[1]Savage P A, Klawon D E J, Miller C H. Regulatory T cell development[J]. Annu Rev Immunol, 2020, 38: 421-453.
[2]Chen W J, Jin W W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3[J]. J Exp Med, 2003, 198(12): 1875-1886.
[3]Levine A G, Arvey A, Jin W, et al. Continuous requirement for the TCR in regulatory T cell function[J]. Nat Immunol, 2014, 15(11): 1070-1078.
[4]Smigiel K S, Richards E, Srivastava S, et al. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets[J]. J Exp Med, 2014, 211(1): 121-136.
[5]Vahl J C, Drees C, Heger K, et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool[J]. Immunity, 2014, 41(5): 722-736.
[6]Lee W, Lee G R. Transcriptional regulation and development of regulatory T cells[J]. Exp Mol Med, 2018, 50(3): e456.
[7] de Brito C B, Patra A K. NFAT factors are dispensable for the development but are critical for the maintenance of Foxp3+ regulatory T cells[J]. Cells, 2022, 11(9): 1397.
[8]Hövelmeyer N, Schmidt-supprian M, Ohnmacht C. NF-κB in control of regulatory T cell development, identity, and function[J]. J Mol Med (Berl), 2022, 100(7): 985-995.
[9]Ono M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes[J]. Immunology, 2020, 160(1): 24-37.
[10]Shi Y J, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1[J]. Cell, 2004, 119(7): 941-953.
[11]Qin X K, Du Y, Liu X H, et al. LSD1 promotes prostate cancer cell survival by destabilizing FBXW7 at post-translational level[J]. Front Oncol, 2020, 10: 616185.
[12]Hu X, Xiang D X, Xie Y, et al. LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression[J]. Oncogene, 2019, 38(44): 7017-7034.
[13]Hong Y N, Li X F, Zhu J F. LSD1-mediated stabilization of SEPT6 protein activates the TGF-β1 pathway and regulates non-small-cell lung cancer metastasis[J]. Cancer Gene Ther, 2022, 29(2): 189-201.
[14]Fang Y, Liao G C, Yu B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects[J]. J Hematol Oncol, 2019, 12(1): 129.
[15]Stamos D B, Clubb L M, Mitra A, et al. The histone demethylase Lsd1 regulates multiple repressive gene programs during T cell development[J]. J Exp Med, 2021, 218(12): e20202012.
[16]Liu Y, Debo B, Li M F, et al. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade[J]. Nat Commun, 2021, 12(1): 6831.
[17]Kerenyi M A, Shao Z, Hsu Y J, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation[J]. Elife, 2013, 2: e00633.
[18]Lee P P, Fitzpatrick D R, Beard C, et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival[J]. Immunity, 2001, 15(5): 763-774.
[19]Li M O, Rudensky A Y. T cell receptor signalling in the control of regulatory T cell differentiation and function[J]. Nat Rev Immunol, 2016, 16(4): 220-233.
[20]Xiong Y, Wang L Q, Di Giorgio E, et al. Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity[J]. J Clin Invest, 2020, 130(4): 1830-1842.
[21]Song Y, Dagil L, Fairall L, et al. Mechanism of crosstalk between the LSD1 demethylase and HDAC1 deacetylase in the CoREST complex[J]. Cell Rep, 2020, 30(8): 2699-2711.e8.
[22]Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008, 133(5): 775-787.
[23]Liu W, Fan J B, Xu D W, et al. Knockdown of LSD1 ameliorates the severity of rheumatoid arthritis and decreases the function of CD4 T cells in mouse models[J]. Int J Clin Exp Pathol, 2018, 11(1): 333-341.
|